The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial

被引:7
|
作者
Liu, Haiyan [1 ,2 ]
Lan, Xiaofeng [1 ,2 ]
Wang, Chengyu [1 ,2 ]
Zhang, Fan [2 ,3 ]
Fu, Ling [2 ,3 ]
Li, Weicheng [1 ,2 ,3 ]
Ye, Yanxiang [1 ,2 ]
Hu, Zhibo [1 ,2 ]
Chao, Ziyuan [2 ]
Ning, Yuping [1 ,2 ,3 ]
Zhou, Yanling [1 ,2 ]
机构
[1] Guangdong Engn Technol Res Ctr Translat Med Met Di, Guangzhou, Peoples R China
[2] Guangzhou Med Univ, Affiliated Brain Hosp, Guangzhou Huiai Hosp, Guangzhou, Peoples R China
[3] Southern Med Univ, Sch Clin Med 1, Guangzhou, Peoples R China
关键词
Clinical trial; Esketamine; Major depressive disorder; Suicide; ELECTROCONVULSIVE-THERAPY; RATING-SCALE; INTRAVENOUS KETAMINE; ANTIDEPRESSANT; VALIDITY; RELIABILITY; SEVERITY; PHARMACOKINETICS; ADOLESCENTS; STATES;
D O I
10.1186/s12888-022-04388-y
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background Major depressive disorder (MDD) is a high risk factor for suicide, with up to 20% of MDD patients attempting suicide during their lifetime. Current treatments for MDD are slow onset of action, low efficiency, and the inability to control suicidal behaviors quickly and effectively. Intravenous ketamine has been shown to have a rapid but transient antidepressant effect, but there is still lack evidence on the efficacy and safety of intravenous esketamine in reducing suicidal ideation and depressive symptoms in MDD patients with suicidal ideation. We designed a study to investigate the effect of short-term repeated intravenous infusion of esketamine three times in MDD patients with suicidal ideation. Methods This study features a randomized, double-blind, placebo-controlled trial (RCT) comparing short-term repeated intravenous infusions of esketamine with placebo as a supplement to conventional antidepressants with an intervention period of 6 days and one infusion every other day, followed by 4 weeks of follow-up. These methods support the examination of the efficacy, safety, tolerability, and mechanism of action of short-term repeated intravenous infusions of esketamine in MDD patients with suicidal ideation. Discussion This is the first RCT to explore the efficacy and safety of short-term repeated infusion of esketamine on suicidal ideation and depressive symptoms in MDD patients with suicidal ideation. If proven effective and tolerated, it will provide evidence for rapid and effective treatment of suicidal ideation and depressive symptoms in MDD individuals with suicidal ideation.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial
    Haiyan Liu
    Xiaofeng Lan
    Chengyu Wang
    Fan Zhang
    Ling Fu
    Weicheng Li
    Yanxiang Ye
    Zhibo Hu
    Ziyuan Chao
    Yuping Ning
    Yanling Zhou
    [J]. BMC Psychiatry, 22
  • [2] Effect of Repeated Intravenous Esketamine on Adolescents With Major Depressive Disorder and Suicidal Ideation: A Randomized Active-Placebo-Controlled Trial
    Zhou, Yanling
    Lan, Xiaofeng
    Wang, Chengyu
    Zhang, Fan
    Liu, Haiyan
    Fu, Ling
    Li, Weicheng
    Ye, Yanxiang
    Hu, Zhibo
    Chao, Ziyuan
    Ning, Yuping
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2024, 63 (05): : 507 - 518
  • [3] Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder
    Kryst, Joanna
    Kawalec, Pawel
    Pilc, Andrzej
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (01) : 9 - 20
  • [4] The Patient Perspective: Esketamine Treatment for Major Depressive Disorder With Active Suicidal Ideation and Intent
    Jamieson, Carol
    Fu, Dong-Jing
    Ionescu, Dawn
    Lane, Rosanne
    Canuso, Carla
    [J]. NEUROPSYCHOPHARMACOLOGY, 2020, 45 (SUPPL 1) : 222 - 222
  • [5] Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials
    Diekamp, Bettina
    Borentain, Stephane
    Fu, Dong-Jing
    Murray, Robert
    Heerlein, Kristin
    Zhang, Qiaoyi
    Schuele, Cornelius
    Mathews, Maju
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2021, 17 : 2347 - 2357
  • [6] Short-term cognitive effects of repeated-dose esketamine in adolescents with major depressive disorder and suicidal ideation: a randomized controlled trial
    Lan, Xiaofeng
    Wang, Chengyu
    Zhang, Fan
    Liu, Haiyan
    Li, Weicheng
    Ye, Yanxiang
    Hu, Zhibo
    Mai, Siming
    Ning, Yuping
    Zhou, Yanling
    [J]. CHILD AND ADOLESCENT PSYCHIATRY AND MENTAL HEALTH, 2023, 17 (01)
  • [7] Short-term cognitive effects of repeated-dose esketamine in adolescents with major depressive disorder and suicidal ideation: a randomized controlled trial
    Xiaofeng Lan
    Chengyu Wang
    Fan Zhang
    Haiyan Liu
    Weicheng Li
    Yanxiang Ye
    Zhibo Hu
    Siming Mai
    Yuping Ning
    Yanling Zhou
    [J]. Child and Adolescent Psychiatry and Mental Health, 17
  • [8] Efficacy and Safety of Curcumin in Major Depressive Disorder: A Randomized Controlled Trial
    Sanmukhani, Jayesh
    Satodia, Vimal
    Trivedi, Jaladhi
    Patel, Tejas
    Tiwari, Deepak
    Panchal, Bharat
    Goel, Ajay
    Tripathi, Chandra Bhanu
    [J]. PHYTOTHERAPY RESEARCH, 2014, 28 (04) : 579 - 585
  • [9] A randomized controlled dosing study of Iyengar yoga and coherent breathing for the treatment of major depressive disorder: Impact on suicidal ideation and safety findings
    Nyer, Maren
    Gerbarg, Patricia L.
    Silveri, Marisa M.
    Johnston, Jennifer
    Scott, Tammy M.
    Nauphal, Maya
    Owen, Liz
    Nielsen, Greylin H.
    Mischoulon, David
    Brown, Richard P.
    Fava, Maurizio
    Streeter, Chris C.
    [J]. COMPLEMENTARY THERAPIES IN MEDICINE, 2018, 37 : 136 - 142
  • [10] Efficacy and safety of repeated ketamine infusion in major depressive disorder with suicidal ideation
    Goyal, Shri Gopal
    Verma, K. K.
    Singh, Ripu Daman
    Baniya, Girish Chandra
    [J]. INDIAN JOURNAL OF PSYCHIATRY, 2018, 60 (05) : 111 - 111